Clazakizumab for the Treatment of Chronic Active Antibody Mediated

See also
Status	Clinical Trial	Phase
Completed	`NCT02533596` - Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange	N/A
Completed	`NCT04367610` - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Completed	`NCT05021484` - Felzartamab in Late Antibody-Mediated Rejection	Phase 2
Terminated	`NCT02120482` - Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study	N/A
Terminated	`NCT03221842` - Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients	Phase 3
Terminated	`NCT01895127` - Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation	Phase 2
Completed	`NCT02013037` - The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation	Phase 3
Recruiting	`NCT03737136` - Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR	N/A
Recruiting	`NCT05913596` - The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation	N/A
Active, not recruiting	`NCT04541914` - Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT	N/A
Withdrawn	`NCT03805178` - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization	Phase 2
Recruiting	`NCT06112951` - A Prospective Randomized Trial of ECP in Subclinical AMR	N/A
Active, not recruiting	`NCT04897438` - Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection	N/A
Recruiting	`NCT05004493` - Biorepository and Registry for Plasma Exchange Patients
Completed	`NCT04026087` - Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
Active, not recruiting	`NCT03994783` - Transplant Antibody-Mediated Rejection: Guiding Effective Treatments	Phase 3
Not yet recruiting	`NCT05862766` - Isatuximab in Lung Transplant Recipients	Early Phase 1
Recruiting	`NCT04368962` - DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
Completed	`NCT03444103` - A Pilot Trial of Clazakizumab in Late ABMR	Phase 2
Recruiting	`NCT05140018` - Incidence, Course and Outcome of ABMR in Kidney Transplantation

NCT number	NCT03744910
Study type	Interventional
Source	CSL Behring
Contact
Status	Terminated
Phase	Phase 3
Start date	October 14, 2019
Completion date	April 8, 2024

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients — IMAGINE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms